The present disclosure relates to a highly stable basic fibroblast growth factor mutant, and a use thereof. Specifically, the present disclosure provides: a highly stable basic fibroblast growth factor mutant, in which two or more amino acids in an amino acid sequence of SEQ ID NO.: 1 are substituted with serine and one or more amino acids are substituted with cysteine； a DNA base sequence encoding the bFGF mutant； an expression vector including the DNA base sequence； a transformant transformed by the expression vector； a method of producing the bFGF mutant； and a composition including the bFGF mutant as an active ingredient. According to the present disclosure, the bFGF mutant of the present disclosure has excellent stability in an aqueous solution state and excellent thermal stability, and thus it is possible to produce functional cosmetics and skin inflammation medicines which do not lose activity, even during distribution and storage.
